FUBP1 and Patent ductus arteriosus: This indicates that high levels of anti-FUBP1 aAb mirror its high expression in PDA and prompted us to hypothesize that monitoring anti-FUBP1 aAb can be used to evaluate changes in FUBP1 tumor tissue expression and eventually target FUBP1 to reduce tumor burden [43].